Skip to main content

Table 1 Patient and tumor characteristics

From: Docetaxel- and 5-FU-concurrent radiotherapy in patients presenting unresectable locally advanced pancreatic cancer: a FNCLCC-ACCORD/0201 randomized phase II trial's pre-planned analysis and case report of a 5.5-year disease-free survival

 

Patients

%

Sex

  

   Female

9

45%

   Male

11

55%

Age

  

   ≤ 60 years

9

45%

   > 60 year

11

55%

   Median [min - max]

62 [44 - 74]

-

Performance status

  

   80%

7

35%

   90%

7

35%

   100%

6

30%

Diagnostic method

  

   Histologic

7

35%

   Cytologic

13

65%

Tumor differentiation

  

   Well

7

35%

   Moderately

1

5%

   Poorly or not

6

30%

   Missing

6

30%

TNM classification*

  

   T2N0

1

5%

   T3N0

4

20%

   T3N1

4

20%

   T4N0

3

15%

   T4N1

4

20%

   Missing**

4

20%

Localization

  

   Head and body

1

5%

   Head alone

14

70%

   Body alone

4

20%

   Tail alone

1

5%

Size of lesions (mm)***

  

   Primitive

39 [10 - 79]

   Primitive + lymph nodes

42 [10 - 79]

Total

20

100%

  1. *All tumors were M0
  2. ** Missing: 1 T3Nx (1), T4Nx (2) and TxNx (1)
  3. *** Median size and range for the longest tumoral diameter, data missing for one patient